NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

October 31, 2025

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

October 05, 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

October 02, 2025

Joshua K. Sabari, MD, discusses the significance of the FDA approval of first-line maintenance therapy with lurbinectedin plus atezolizumab for ES-SCLC.

October 02, 2025

The FDA approved lurbinectedin plus atezolizumab as first-line maintenance for ES-SCLC that has not progressed after frontline induction therapy.

September 09, 2025

Narjust Florez, MD, and Joshua K. Sabari, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

September 04, 2025

Drs Seery, Oberstein, and Pathak discuss data from the NAPOLI 3 trial of NALIRIFOX vs nab-paclitaxel and gemcitabine in treatment-naive pancreatic cancer.

September 02, 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

July 24, 2025

Dr Sabari highlights key research investigating telisotuzumab vedotin in patients with c-Met–overexpressing non–small cell lung cancer.

July 23, 2025

Elaine Shum, MD, discusses questions that remain regarding the first-line treatment paradigm for patients with EGFR-mutant non–small cell lung cancer.

July 20, 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

July 18, 2025

Joshua K. Sabari, MD, discusses response rates observed with zidesamtinib in patients with advanced ROS1-positive non–small cell lung cancer.

July 16, 2025

Drs Gerber and Patel discuss a study they conducted investigating the use of IHC as a biomarker for early TP53 mutation identification in MDS and AML.

July 13, 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

June 23, 2025

Olivia Fankuchen, MD, MS, highlights molecular targets, trial data, and real-world experiences that have immediate implications for the lung cancer field.

June 11, 2025

Joshua Sabari, MD, explains the rationale behind targeting c-MET in nonsquamous EGFR wild-type advanced NSCLC.

June 04, 2025

In an OncLive Peer Exchange, expert investigators convened to discuss the treatment landscape of early-stage NSCLC from a multidisciplinary perspective.

May 15, 2025

Joshua K. Sabari, MD, discusses how phase 1 efficacy data with zongertinib in HER2-mutant NSCLC lay the foundation for future research with the agent.

May 11, 2025

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

April 24, 2025

Paul E. Oberstein, MD, discusses the clinical applications of the Oncodetect test for molecular residual disease detection in patients with solid tumors.

April 03, 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss ongoing research and areas of potential investigation in ovarian cancer.